ライフサイエンスコーパス: premenstrual

1 pment and initial validation of the Carolina Premenstrual Assessment Scoring System (C-PASS).

2 than the placebo group as assessed by total premenstrual Daily Symptom Rating Form scores for 3 trea

3 Premenstrual dosing does not differ from continuous dosi

4 has been linked to the use of this drug for premenstrual dsyphoria.

5 % of the nondepressed women met criteria for premenstrual dysphoria (symptom cyclicity and at least m

6 The role of ovarian steroids in both premenstrual dysphoria and perimenopausal depression has

7 icantly better than placebo for treatment of premenstrual dysphoria as reflected by symptomatic impro

8 neither menses-related symptom cyclicity nor premenstrual dysphoria was an invariant accompaniment of

9 Additionally, the rate of premenstrual dysphoria was not predicted by initial self

10 rate of menses-related symptom cyclicity and premenstrual dysphoria was observed in perimenopausal de

11 re useful therapeutic options for women with premenstrual dysphoria.

12 id metabolite allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomat

13 strual cycle in healthy women and those with premenstrual dysphoric disorder (PMDD) and that a menstr

14 Despite evidence for the validity of premenstrual dysphoric disorder (PMDD) and the inclusion

15 There is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically s

16 other psychiatric illnesses tested, although premenstrual dysphoric disorder (PMDD) may be an excepti

17 Premenstrual dysphoric disorder (PMDD) symptoms are elim

18 bitors (SRIs) are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily

19 uggests that mood and behavioral symptoms in premenstrual dysphoric disorder (PMDD), a common, recent

20 ; most of these women also meet criteria for premenstrual dysphoric disorder (PMDD).

21 h catamenial epilepsy and enhance anxiety in premenstrual dysphoric disorder (PMDD).

22 Patients with premenstrual dysphoric disorder (whose symptoms had remi

23 acebo-controlled protocol to nine women with premenstrual dysphoric disorder and 11 healthy female vo

24 a GABA levels were measured in 27 women with premenstrual dysphoric disorder and 21 comparison women

25 Women with premenstrual dysphoric disorder and a past history of ma

26 order, 21 with major depression, and 10 with premenstrual dysphoric disorder and in 34 normal compari

27 roup of experts to examine the literature on premenstrual dysphoric disorder and provide recommendati

28 equested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200

29 Premenstrual dysphoric disorder appears to be associated

30 tients with panic disorder and patients with premenstrual dysphoric disorder are highly susceptible t

31 In women with premenstrual dysphoric disorder but no past major depres

32 the hypothesis of serotonergic deficiency in premenstrual dysphoric disorder by measuring the prolact

33 The patients with premenstrual dysphoric disorder experienced a return of

34 pared to the normal subjects, the women with premenstrual dysphoric disorder had a significantly blun

35 e whether efficacy for premenstrual syndrome/premenstrual dysphoric disorder is a general or more ser

36 Premenstrual dysphoric disorder is an important cause of

37 Premenstrual dysphoric disorder is often associated with

38 e disorder and a state-dependent decrease in premenstrual dysphoric disorder might imply a possible c

39 The panic rate for patients with premenstrual dysphoric disorder was similar to that for

40 thors sought to determine whether women with premenstrual dysphoric disorder with or without prior ma

41 nic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and social phobia.

42 ents with major depression and patients with premenstrual dysphoric disorder, respectively).

43 Premenstrual dysphoric disorder, which affects 2%-5% of

44 ction may be involved in the pathogenesis of premenstrual dysphoric disorder.

45 disorders, such as postpartum depression and premenstrual dysphoric disorder.

46 ission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.

47 in reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder.

48 fective for severe premenstrual syndrome and premenstrual dysphoric disorder.

49 ical link between subtypes of depressive and premenstrual dysphoric disorders.

50 women recruited for retrospectively reported premenstrual emotional symptoms provided two to four mon

51 women recruited for retrospectively reported premenstrual emotional symptoms provided two to four mon

52 o relapse was compared between 66 women with premenstrual exacerbation (51.2%) and 63 without.

53 episodes was compared between 191 women with premenstrual exacerbation (65.2%) and 102 women without.

54 Women with premenstrual exacerbation had a shorter time to relapse

55 Women with premenstrual exacerbation had more depressive and mood e

56 During follow-up, the group with premenstrual exacerbation had more episodes (primarily d

57 Women with bipolar disorder and premenstrual exacerbation have a worse course of illness

58 Premenstrual exacerbation may be a clinical marker predi

59 isorder in prospectively followed women with premenstrual exacerbation.

60 Premenstrual mood symptoms were evaluated in women with

61 resonance imaging in female subjects without premenstrual mood symptoms, we found that OFC activity t

62 first 3 days of menses rather than only the premenstrual phase.

63 Retrospectively reported premenstrual-related symptoms of depression and anxiety

64 Lifetime major depression and premenstrual-related tiredness, sadness, and irritabilit

65 A single premenstrual symptom factor was found that was moderatel

66 previous evidence, retrospective reports of premenstrual symptom increases were a poor predictor of

67 was defined as a decrease of at least 50% in premenstrual symptom score from the pretreatment baselin

68 tic and environmental risk factors for these premenstrual symptoms and lifetime major depression are

69 elationship of the familial risk factors for premenstrual symptoms and major depression.

70 tudies suggest that retrospectively reported premenstrual symptoms are heritable, these studies have

71 the heritability of the stable component of premenstrual symptoms at 56% and showed no impact of fam

72 nd none of the comparison subjects described premenstrual symptoms on self-reports.

73 atment during the interval from the onset of premenstrual symptoms through the first few days of mens

74 However, 5 of 8 premenstrual symptoms were significantly associated with

75 formation on recent menstrual regularity and premenstrual symptoms, as well as on sociodemographic, s

76 not active smoking, higher body mass index, premenstrual symptoms, perceived stress, and age were al

77 ed and 9% of the nondepressed women reported premenstrual symptoms.

78 status, cigarette smoking, nulliparity, and premenstrual symptoms.

79 Women without premenstrual syndrome (normal women) participated in a s

80 Clinically significant premenstrual syndrome (PMS) affects 15-20% of premenopau

81 Moderate to severe premenstrual syndrome (PMS) affects as many as 20% of pr

82 (4) and delta subunits, using a rat model of premenstrual syndrome (PMS) in which 1-3 mM alcohol pref

83 her minerals might impact the development of premenstrual syndrome (PMS) through multiple mechanisms,

84 onses to placebo medication of patients with premenstrual syndrome (PMS) who were randomly assigned i

85 rlying hypertension might also contribute to premenstrual syndrome (PMS), but whether women with PMS

86 Symptoms of premenstrual syndrome (PMS), such as anxiety and seizure

87 cle to cycle symptom stability in women with premenstrual syndrome (PMS).

88 tentially involved in the pathophysiology of premenstrual syndrome (PMS).

89 being used as first-line therapy for severe premenstrual syndrome (PMS).

90 About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also me

91 onin reuptake inhibitor in women with severe premenstrual syndrome and determined the effects of post

92 ogenous 3alpha,5alpha-THP withdrawal such as premenstrual syndrome and postpartum or postmenopausal d

93 reuptake inhibitors are effective for severe premenstrual syndrome and premenstrual dysphoric disorde

94 The symptoms of women with premenstrual syndrome improve in response to suppression

95 er from continuous dosing with sertraline in premenstrual syndrome treatment.

96 The 10 women with premenstrual syndrome who were given leuprolide had a si

97 The 10 women with premenstrual syndrome who were given leuprolide plus est

98 received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone dur

99 menopausal women, alleviate the symptoms of premenstrual syndrome, and reduce persistent urinary tra

100 fter adjusting for smoking, body mass index, premenstrual syndrome, hot flashes, poor sleep, health s

101 ion, including history of depression, severe premenstrual syndrome, poor sleep, age, race, and employ

102 roids have been implicated in the genesis of premenstrual syndrome, postpartum depression, and other

103 In women with premenstrual syndrome, the occurrence of symptoms repres

104 effects of B vitamins in the development of premenstrual syndrome.

105 tory response is unknown in the treatment of premenstrual syndrome.

106 and are important to define in treatment of premenstrual syndrome.

107 and was well tolerated by women with severe premenstrual syndrome.

108 or placebo on symptoms in 20 women with the premenstrual syndrome.

109 contributed only modestly to the etiology of premenstrual syndrome.

110 depressant to determine whether efficacy for premenstrual syndrome/premenstrual dysphoric disorder is

111 Primary outcome measures were the Rating for Premenstrual Tension observer and self-ratings completed

112 Premenstrual Tension Scale (PMTS) score was the primary

113 Finally, the Rating for Premenstrual Tension scores in the second and third estr

114 and observer-rated scores on the Rating for Premenstrual Tension were significantly increased (more

115 were noted in prevalence or colony counts at premenstrual versus mid- and postmenstrual visits for mo

116 four measured negative mood symptoms in the premenstrual versus the postmenstrual week); 5 of these

117 gnificantly different between tampons at the premenstrual visit, when unusually low values were obser